Discussion
AML
DISEASE PROGRESSION, RECRUITMENT, AML
This article describes the feasibility, safety, and tolerability of an allogeneic haploidentical γδ T lymphocyte product, which can become an off-the-shelf therapeutic, suitable for investigation of therapeutic potential across multiple indications. Strategies to elicit durable clinical response are required for the treatment of myeloid malignancies.γδ T lymphocytes represent an emerging field with several previous clinical trials in small numbers of patients providing preliminary evidence of safety and feasibility. A 2014 systematic review of clinical trials involving in vivo expansion or adoptive transfer of γδ T lymphocytes identified 12 relevant studies including 157 patients, of which 7 trials (77 patients) involved adoptive transfer of Recruitment to an earlier clinical study of autologous Therefore, the TCB-202-001 trial investigated the safety and feasibility of infusion of In the patient achieving MLFS, despite the MRD levels showing a sustained reduction from the baseline value, there was subsequent increase in bone marrow blast count after the second and third infusions indicative of disease progression. In studies with αβ T cells, leukemic blasts are known to adopt multiple mechanisms of immune evasion including secretion of immunoinhibitory factors inducing regulatory T cells (Tregs)A limitation of allogeneic γδ T cell approaches is the risk of graft rejection. In our study, lymphodepleting conditioning chemotherapy was used, both to limit rejection and to create space and access to homeostatic cytokines to promote expansion.The promising, preliminary data of a favorable safety profile in late-stage AML patients paves the way for future clinical studies looking at early-treatment AML patients not responding to initial therapy. We are, therefore, now progressing a phase II pivotal clinical trial using an off-the-shelf, unrelated allogeneic donor source of γδ T-cells expanded 